N/A N=12 Erectile Rating During the Treatment of Rectal Cancers Localized
Rectal Cancer Stage I
Primary: Proportion of Patients With Erectile Dysfunction Induced by Medical and Surgical Treatment of Rectal Cancer — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=583 A Study of Tadalafil After Radical Prostatectomy
Erectile Dysfunction
Primary: Percentage of Participants With a Score of Greater Than or Equal to 22 in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF)…
N/A N=20 MED3000 Topical Gel for On-Demand Treatment of Post-Radical Prostatectomy Erectile Dysfunction
Erectile Dysfunction Following Radical Prostatectomy
Primary: Whether the Erectile Function Domain of the International Index of Erectile Function Mean Change From Baseline Met or Exceeded the Minimally Clinically Important…
N/A N=6 Intra-operative Assessment of Cavernosal Nerve Stimulus Threshold
Prostatectomy
Primary: Maximum Cavernosal Nerve Stimulation Threshold — 7.5 mA
Phase 2 N=56 Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy
Prostate Cancer · Erectile Dysfunction
Primary: Erectile Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire Erectile Function Domain — 14; 19 score on a scale
Phase 3 N=298 Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy
Erectile Dysfunction
Primary: Change in Percentage of Sexual Attempts in Which Subjects Are Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse — 13.9; 28.0; 29.4…
Phase 2 N=135 Vessel Sparing Prostate Radiation Therapy
Cancer of the PROSTATE
Primary: The Percentage of Patients Able to be Sexually Active With or Without the Use of Aids — 88 percentage of patients
Phase 4 N=131 A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
Erectile Dysfunction · Prostate Cancer
Primary: Erectile Function Domain Score Between Treated and Untreated Groups — 18.0; 23.5 Erectile Function Domain Score — p=0.111
N/A N=82 Penile Length Maintenance Post-Prostatectomy
Prostate Cancer · Penile Diseases
Primary: Change in Penile Length — 0.3; 1.6 centimeters
Phase 3 N=290 Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer
Prostate Cancer · Erectile Dysfunction
Primary: Assessment of Erectile Dysfunction — 64; 64; 59.00; 58 units on a scale
N/A N=80 Radial Shockwave Therapy for Erectile Dysfunction
Erectile Dysfunction
Primary: Change IIEF-EF Score — 3.4; 4.2 units on a scale
Phase 3 N=242 Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy
Prostate Cancer · Sexual Dysfunction
Primary: Percentage of Patients Maintaining Spontaneous (Off-drug) Erectile Function (EF) at Weeks 28-30 After Initiation of Radiation Therapy (RT) — 79; 74 percentage of…
Phase 2 N=14 Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer
Male Erectile Disorder · Prostate Adenocarcinoma · Erectile Dysfunction, CTCAE
Primary: Change in International Index of Erectile Function (IIEF) Scores — 0; 0; 0 Participants
Phase 2 N=140 L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors
Male Erectile Disorder · Prostate Cancer · Radiation Toxicity
Primary: International Index of Erectile Function (IIEF) — 14.62; 14.26; 11.82 units on a scale
N/A N=90 Outcomes and Efficacy of Ejaculatory Preserving Transurethral Resection of Prostate
Ejaculatory Dysfunction · BPH
Primary: Preservation of Ejaculation — 34; 8 Participants
N/A N=208 Conservative Treatment of Postprostatectomy Incontinence
Urinary Incontinence
Primary: Percent Change in Incontinence Episodes on Bladder Diary — 55; 51; 24 % change in episodes per week — p=.001
N/A N=40 Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
Urinary Incontinence
Primary: Time to Continence — 95 Days to Continence
N/A N=178 Sexual Function and Wellbeing in Males With Rectal Cancer
Rectal Cancer
Primary: Change in Serum Testosterone Levels Between Baseline and After Preoperative Radiotherapy. — 11.3; 11.9; 9.3 nmol/L — p=0.014
Phase 4 N=623 A Study in Erectile Dysfunction
Erectile Dysfunction
Primary: Percentage of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week…
Phase 1 N=59 Shockwave Therapy and Platelet Rich Plasma for the Treatment of Erectile Dysfunction
Erectile Dysfunction
Primary: Number of Participants With Treatment Emergent Serious Adverse Events (TE-SAEs) During the Study Period. — 0; 0 Participants
N/A N=738 Use of Hypothermia During Robotic Prostatectomy
Prostate Cancer
Primary: Feasibility and Safety Using an Improved, More Efficient and Less Labor Intensive Cooling Balloon in Patients Undergoing Hypothermic Nerve-sparing RLP in Participants…
N/A N=1,457 PROPPER Prospective Registry of Outcomes With Penile Prosthesis
Erectile Dysfunction · Impotence
Primary: Number of Participants With Penile Prosthesis Overall Subject Satisfaction — 34; 34; 0; 0 Participants
N/A N=403 Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors
Prostatic Neoplasm
Primary: Urinary Function Scores — 80.1; 81.4 Scores on a scale (0-100)
N/A N=40 Evaluation of the Coloplast Titan® IPP for Maintaining Penile Length While Treating Erectile Dysfunction (ED)
Erectile Dysfunction
Primary: The Study's Primary Objective Will Assess the Change in Penile Length. — 1.14; 0.99; 1.04; 0.94 cm
N/A N=24 Platelet Rich Plasma During Radical Prostatectomy
Prostate Cancer
Primary: Safety of Using Platelet Rich Plasma (PRP) on the Neurovascular Bundle (NVB) — 0; 2; 17 Participants
N/A N=140 Prostate Cancer - Patient Empowerment Program
Prostate Cancer
Primary: Proportion of Participants With Clinically Significant Psychological Distress (Kessler Psychological Distress Scale-10 ≥20) — 9; 14; 57; 48 Participants — p=0.031
Phase 3 N=120 Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery
Urinary Incontinence
Primary: Urinary Continence Recovery — 25; 5 grams
N/A N=103 Safety and Efficacy of Low Intensity Shockwave for the Treatment of Erectile Dysfunction
Vasculogenic Erectile Dysfunction
Primary: International Index of Erectile Function (IIEF-EF) Questionnaire — 18; 17.9; 20.5; 19.7 score on a scale — p=<0.007
Phase 2 N=40 PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Prostate Neoplasms
Primary: The Purpose of the Present Study is to Assess the Safety of PS-341 as a Pretreatment in Patients Who Are to Undergo a Radical Prostatectomy. Poor Wound Healing and…
Phase 3 N=70 Botulinum Toxin for Erectile Dysfunction
Sexual Dysfunction · Erectile Dysfunction
Primary: Right (PSV R) and Left (PSV L) Cavernosal Artery Mean PSV Before Treatment — 34.52; 30.85; 34.33; 31.73 cm/sec